Patricia A. Gabow | Academic Influence

Why Is Patricia A. Gabow Influential?

According to Wikipedia, Patricia Anne Acquaviva Gabow is an American academic physician, medical researcher, healthcare executive, author and lecturer. Specializing in nephrology, she joined the department of medicine, division of renal diseases, at the University of Colorado School of Medicine in 1973, advancing to a full professorship in 1987; she is presently Professor Emerita. She was the principal investigator on the National Institutes of Health Human Polycystic Kidney Disease research grant, which ran from 1985 to 1999, and defined the clinical manifestations and genetics of the disease in adults and children. She served for two decades as CEO of Denver Health, an integrated public healthcare system in Denver, Colorado, where she implemented numerous business-based systems to streamline operations, improve patient care, and recognize cost savings. In particular, her introduction of the "Lean" quality-improvement system, based on the Toyota Production System, earned her national recognition. She is the author of more than 150 articles and book chapters, three books, and has received numerous awards for excellence in teaching, physician care, and leadership. She was inducted into the Colorado Women's Hall of Fame in 2004.

Patricia A. Gabow's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Papers

PKD2, a Gene for Polycystic Kidney Disease That Encodes an Integral Membrane Protein (1275)
The Spectrum of Rhabdomyolysis (848)
Autosomal dominant polycystic kidney disease. (417)
Urinary diagnostic indices in acute renal failure: a prospective study. (360)
The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. (356)
Autosomal dominant polycystic kidney disease. (338)
Causes of death in autosomal dominant polycystic kidney disease. (308)
Autosomal dominant polycystic kidney disease: localization of the second gene to chromosome 4q13-q23. (257)
Autosomal dominant polycystic kidney disease--more than a renal disease. (253)
Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease (250)
Nonoliguric acute renal failure. (247)
Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. (245)
Linkage heterogeneity of autosomal dominant polycystic kidney disease. (226)
Syndromes of toluene sniffing in adults. (221)
Renal structure and hypertension in autosomal dominant polycystic kidney disease. (220)
Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease (213)
Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. (207)
Echocardiographic findings in autosomal dominant polycystic kidney disease. (200)
Intracranial aneurysms in autosomal dominant polycystic kidney disease. (183)
Polycystic kidney disease: prospective analysis of nonazotemic patients and family members. (181)
Diagnostic importance of an increased serum anion gap. (178)
Disorders associated with an altered anion gap. (171)
For many patients who use large amounts of health care services, the need is intense yet temporary. (169)
Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. (162)
The fall of the serum anion gap. (143)
Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. (142)
Progression of autosomal-dominant polycystic kidney disease in children. (137)
Hereditary and acquired cystic disease of the kidney. (134)
Autosomal dominant polycystic kidney disease in childhood: a longitudinal study. (128)
THE COMMONWEALTH FUND Commission on a High Performance Health System (120)
Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney disease. (119)
Organic acids in ethylene glycol intoxication. (118)
A new method for studying human polycystic kidney disease epithelia in culture. (116)
The clinical utility of renal concentrating capacity in polycystic kidney disease. (115)
The spectrum of autosomal dominant polycystic kidney disease in children. (114)
Denver Health: A Model for the Integration of a Public Hospital and Community Health Centers (108)
Clinical profiles of gross hematuria in autosomal dominant polycystic kidney disease. (106)
Hypertension in autosomal dominant polycystic kidney disease. (105)
Polycystic liver disease: Quantitation of parenchymal and cyst volumes from computed tomography images and clinical correlates of hepatic cysts (102)
The role of alcohol in new-onset atrial fibrillation. (101)
Unrecognized Adult Salicylate Intoxication (99)
Characteristics of very early onset autosomal dominant polycystic kidney disease (97)
Diuretics versus Angiotensin-Converting Enzyme Inhibitors in Autosomal Dominant Polycystic Kidney Disease (96)
Abnormal extracellular matrix and excessive growth of human adult polycystic kidney disease epithelia (96)
Diagnosis of autosomal dominant polycystic kidney disease in utero and in the young infant. (95)
Ten strategies to lower costs, improve quality, and engage patients: the view from leading health system CEOs. (90)
The Effect of Automated Alerts on Provider Ordering Behavior in an Outpatient Setting (89)
Mutation detection of PKD1 identifies a novel mutation common to three families with aneurysms and/or very-early-onset disease. (89)
Anatomic and metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease. (89)
Hypertension in autosomal dominant polycystic kidney disease. (89)
Prevalence of psychiatric disorders and costs of care among adult enrollees in a Medicaid HMO. (86)
Pregnancy outcome and its relationship to progression of renal failure in autosomal dominant polycystic kidney disease. (86)
Cardiovascular abnormalities in children with autosomal dominant polycystic kidney disease. (83)
Attitudes of at-risk and affected individuals regarding presymptomatic testing for autosomal dominant polycystic kidney disease. (81)
Acid-base disturbances in the salicylate-intoxicated adult. (75)
Polycystic kidney disease: clues to pathogenesis. (72)
Toluene Abuse During Pregnancy: Obstetric Complications and Perinatal Outcomes (70)
Recurrence of intracranial aneurysms in autosomal-dominant polycystic kidney disease. (68)
Familial clustering of ruptured intracranial aneurysms in autosomal dominant polycystic kidney disease. (66)
Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history. (65)
Repeat imaging for intracranial aneurysms in patients with autosomal dominant polycystic kidney disease with initially negative studies: a prospective ten-year follow-up. (62)
Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease. (61)
Spironolactone-induced hyperchloremic acidosis in cirrhosis. (61)
Reversible renal failure associated with angiotensin-converting enzyme inhibitors in polycystic kidney disease. (60)
Evaluation of colonic diverticular disease in autosomal dominant polycystic kidney disease without end-stage renal disease. (60)
Is there evidence for anticipation in autosomal-dominant polycystic kidney disease? (58)
Introduction: Autosomal Dominant Polycystic Kidney Disease (58)
Frequently nebulized β-agonists for asthma : effects on serum electrolytes (57)
Utility of ultrasonography in the diagnosis of autosomal dominant polycystic kidney disease in children. (57)
Natural history of autosomal dominant polycystic kidney disease. (54)
Tubulointerstitial and glomerular nephritis associated with rifampin. Report of a case. (52)
Effect of Child Health Insurance Plan enrollment on the utilization of health care services by children using a public safety net system. (51)
Fanconi's syndrome and distal renal tubular acidosis after glue sniffing. (51)
RENAL CELL CARCINOMA: UNUSUAL SYSTEMIC MANIFESTATIONS (50)
Evaluating patient compliance with nurse advice line recommendations and the impact on healthcare costs. (50)
Autosomal dominant polycystic kidney disease in blacks: clinical course and effects of sickle-cell hemoglobin. (48)
Factors relating to urinary protein excretion in children with autosomal dominant polycystic kidney disease. (47)
Innovation and Best Practices in Health Care Scheduling (47)
Observations of Residents’ Work Activities for 24 Consecutive Hours: Implications for Workflow Redesign (47)
Intracranial aneurysms in patients with autosomal dominant polycystic kidney disease: how to diagnose and who to screen. (44)
Concepts and controversies in salicylate toxicity. (44)
Unrecognized adult salicylate intoxication. (43)
Renal asymmetry in children with autosomal dominant polycystic kidney disease. (42)
CF gene and cystic fibrosis transmembrane conductance regulator expression in autosomal dominant polycystic kidney disease. (41)
Percutaneous cyst puncture in the treatment of cyst infection in autosomal dominant polycystic kidney disease. (38)
Using computerized clinical decision support for latent tuberculosis infection screening. (35)
Progress in blood pressure control in autosomal dominant polycystic kidney disease. (33)
Segregation analysis of autosomal dominant polycystic kidney disease (30)
Urinary chloride concentration in acute renal failure. (28)
Can America’s Urban Safety Net Systems be a Solution to Unequal Treatment? (27)
Frequently nebulized beta-agonists for asthma: effects on serum electrolytes. (27)
Renal manifestations: complication management and long-term outcome of autosomal dominant polycystic kidney disease. (27)
Uric acid handling in autosomal dominant polycystic kidney disease with normal filtration rates. (25)
A broad and structured approach to improving patient safety and quality: lessons from Denver Health. (25)
Marshaling leadership for high-value health care: an Institute of Medicine discussion paper. (22)
A CEO Checklist for High-Value Health Care (22)
Comparison of Hospitalization Between Nursing Home and Community Residents (21)
Frequency of ovarian cysts in patients with autosomal dominant polycystic kidney disease. (20)
Ethylene glycol intoxication. (20)
Furosemide-induced reduction in ionized calcium in hypoparathyroid patients. (18)
Severe acid-base abnormalities associated with cocaine abuse. (17)
Von Hippel-Lindau disease masquerading as autosomal dominant polycystic kidney disease. (16)
Intra- and extracellular proteins in human normal and polycystic kidney epithelial cells. (16)
A peer approach to high risk youth. (14)
Insurance for autosomal dominant polycystic kidney disease patients prior to end-stage renal disease. (14)
Pathophysiology of adult polycystic kidney disease. (12)
Changes in Insurance Status and Access to Care in an Integrated Safety Net Healthcare System (11)
Psychogenic adipsia in a patient with psychotic depression. (10)
Clinical effect of morning report. (10)
Marked elevations of serum alkaline phosphatase in patients with AIDS. (9)
The Lean Prescription: Powerful Medicine for Our Ailing Healthcare System (9)
Prediction of Likelihood of Polycystic Kidney Disease in the Fetus When a Parent has Autosomal Dominant Polycystic Kidney Disease (7)
Nephrotoxicity following single dose mithramycin therapy. (7)
Prevention of hypercalcemia-induced renal concentrating defect and tissue calcium accumulation. (6)
Exclusion of autosomal dominant polycystic kidney disease type II (ADPKD2) from 160 cM of chromosome 1. (6)
The fall: aligning the best care with standards of care at the end of life. (6)
Perspective: Denver Health: Initiatives for Survival (5)
Genetic studies in a black family with autosomal dominant polycystic kidney disease and sickle-cell trait. (5)
Denver Health: initiatives for survival. (4)
Adrenal insufficiency after unilateral radical nephrectomy. (4)
Closing the Health Care Gap in Communities: A Safety Net System Approach (3)
Denver Health. Transforming care across the continuum. (3)
Improving identification of and intervention for alcoholism. (3)
Outcomes and Lessons Learned (2)
Population Health in Primary Care: Cost, Quality, and Experience Impact (2)
Making a public hospital work. (2)
Improvements in billing processes and information systems increase cash collections in a public health care system. (2)
Early Polycystic Kidney Disease (1)
VIGNETTE IN CLINICAL PATHOPHYSIOLOGY Ethylene Glycol Intoxication (1)
Genetic linkage studies of autosomal dominant polycystic kidney disease: search for the second gene in a large Sicilian family (1)
Separate or United: The Safety Net in the Era of Health Care Integration (1)
Court-Ordered Alcohol Treatment for Patients with Medical Problems (1)
Lean Tool Box (1)
Epidemiology of Autosomal Dominant Polycystic Kidney Disease: Implications for Genetic Counseling (1)
From the bedside to the boardroom. (1)
Futile care: prevention and process: educating patients about advance directives is crucial. (1)
Fluids and electrolytes (0)
Why Pick Lean for Healthcare Transformation (0)
Follow the evidence. Administrative rules, regulations should get comparative-effectiveness treatment. (0)
Leaders' engagement key to process of eliminating waste, respecting patients. (0)
Subject Index Vol. 72, 1996 (0)
Viewpoint on Comprehensive Medicaid Reform. (0)
Metrics, Reporting, and Information Archiving (0)
Why Worry about American Healthcare (0)
Genetic Counseling in ESRD Patients with Polycystic Kidney Disease (0)
Structure for Lean Implementation (0)
Now You Are a Leader (0)
Why Should Women Lead? (0)
Urinary Diagnostic Indices in Acute Renal Failure (0)
Even Leaders Have a Boss (0)
You Can’t Parachute into Leadership (0)
1630 THE NATURAL HISTORY OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE IN CHILDREN (0)
Making the Trains Run on Time and Laying New Tracks (0)
12 Autosomal Dominant Polycystic Kidney Disease (0)
First Things First (0)
Sharing and Receiving Lessons Learned (0)
Role of Leadership in Health System Transformation (0)
Patricia Gabow Comments. (0)
Arteriovenous fistula from drug abuse. Implications for hemodialysis. (0)
Remember the Obvious (0)
The Promise of Lean Processes (0)
Toyota Principles and Working Concepts of Lean (0)
Autosomal Dominant Polycystic Kidney Disease in Blacks : Clinical Course and Effects of Sickle-Cell Hemoglobin 1 (0)
An 'open door' for the vulnerable. Even after reform is in place, need for safety net providers will be great. (0)
Obstacles and Opportunities (0)
POLYCYSTIC KIDNEY DISEASE AND ANGIOTENSIN-CONVERTING ENZYME INHIBITORS. AUTHOR'S REPLY (0)
AUTHORS Lisa Brandenburg President Seattle Children ’ s Hospital Patricia Gabow Former Chief Executive Officer Denver Health Glenn Steele President and Chief Executive Officer Geisinger Health System John Toussaint Chief Executive Officer ThedaCare Center for Healthcare Value (0)
Geographic disparity. Excluding some of the poorest from health reform shouldn't be an option. (0)
Lay of the Land (0)
Inspired leadership: Dr. Patricia Gabow talks about pursuing transformation and why mentoring matters. (0)
TIME’S NOW for WOMEN HEALTHCARE LEADERS (0)
Contents, Vol. 72, 1996 (0)
Reflections of Women Leaders (0)
Standards Of Care: The Author Replies. (0)

This paper list is powered by the following services:

Other Resources About Patricia A. Gabow

What Schools Are Affiliated With Patricia A. Gabow?

Patricia A. Gabow is affiliated with the following schools: